<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091360</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-MD-201</org_study_id>
    <nct_id>NCT04091360</nct_id>
  </id_info>
  <brief_title>A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Phase II, Randomised Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Pressurised Metered Dose Inhaler in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find the best dose of RPL554 for treating the symptoms of
      COPD. COPD is a progressive disease that effects the lungs. In this study single doses will
      be given in the Part A of the study. The information from Part A will be used to decide the
      best doses to be used in Part B. In this part, patients will take 4-5 different doses, each
      for a week to decide which dose best treats the symptoms of COPD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Pharmacokinetic parameter AUC0-12</measure>
    <time_frame>12 hours</time_frame>
    <description>Area under the curve from 0 to 12 hours after drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Pharmacokinetic parameter AUC0-t</measure>
    <time_frame>1 day</time_frame>
    <description>Area under the curve at maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Pharmacokinetic parameter half-life</measure>
    <time_frame>1 day</time_frame>
    <description>Half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Peak FEV1 (forced expiratory volume)</measure>
    <time_frame>Baseline to treatment period 5 day 7, which is approximately 70 days</time_frame>
    <description>Change from baseline in Peak FEV1 measured after morning dosing on Day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and tolerability / Hematology Safety Assessments</measure>
    <time_frame>1 day</time_frame>
    <description>Number of patients with treatment-emergent hematology abnormal laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and tolerability / Blood Chemistry Safety Assessments: Number of patients with treatment-emergent blood chemistry abnormal laboratory assessments</measure>
    <time_frame>1 day</time_frame>
    <description>Number of patients with treatment-emergent blood chemistry abnormal laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and tolerability / Urinalysis Safety Assessments: Number of patients with treatment-emergent urinalysis abnormal laboratory assessments</measure>
    <time_frame>1 day</time_frame>
    <description>Number of patients with treatment-emergent urinalysis abnormal laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and tolerability / ECG - QTcF</measure>
    <time_frame>Start of treatment to day 1</time_frame>
    <description>Number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and tolerability / ECG - Heart Rate</measure>
    <time_frame>Start of treatment to day 1</time_frame>
    <description>Number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and tolerability / Supine vitals signs - Blood pressure</measure>
    <time_frame>Start of treatment to day 1</time_frame>
    <description>Number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and tolerability / Supine vitals signs - Pulse rate</measure>
    <time_frame>Start of treatment to day 1</time_frame>
    <description>Number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Average AUC FEV1 Change from baseline (forced expiratory volume)</measure>
    <time_frame>Start of treatment to day 1</time_frame>
    <description>Change from baseline in average area under the curve 0-4 hours first forced expiratory volume after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Average AUC FEV1 Change from baseline (forced expiratory volume)</measure>
    <time_frame>12 hours</time_frame>
    <description>Change from baseline in average area under the curve 0-12 hours first forced expiratory volume after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Peak FEV1 Change from baseline after single dose</measure>
    <time_frame>Start of treatment to day 1</time_frame>
    <description>Change from baseline in peak first forced expiratory volume after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and tolerability / Hematology safety assessments</measure>
    <time_frame>1 day</time_frame>
    <description>Number of patients with treatment-emergent hematology abnormal laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and tolerability / Blood chemistry safety assessments</measure>
    <time_frame>1 day</time_frame>
    <description>Number of patients with treatment-emergent blood chemistry abnormal laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and tolerability / Urinalysis safety assessments</measure>
    <time_frame>1 day</time_frame>
    <description>Number of patients with treatment-emergent urinalysis abnormal laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and tolerability / ECG - QTcF</measure>
    <time_frame>Start of treatment to day 70</time_frame>
    <description>Number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and tolerability / ECG - Heart rate</measure>
    <time_frame>Start of treatment to day 70</time_frame>
    <description>Number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and tolerability / Supine vital signs - Blood pressure</measure>
    <time_frame>Start of treatment to day 1</time_frame>
    <description>Number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety and tolerability / Supine vital signs - Pulse rate</measure>
    <time_frame>Start of treatment to day 1</time_frame>
    <description>Number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline in trough FEV1</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in morning trough first forced expiratory volume at day 7</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Experimental dose 1 - 100ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 1; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
No. of Puffs per Inhaler = 2; Total Dose = 100ug; Inhaler No.1 = 50ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental dose 2 - 300ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 2; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
No. of Puffs per Inhaler = 2; Total Dose = 300ug; Inhaler No.1 = 150ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental dose 3 - 1000ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 3; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
No. of Puffs per Inhaler = 2; Total Dose = 1000ug; Inhaler No.1 = 500ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental dose 4 - 3000ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 4; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
No. of Puffs per Inhaler = 2; Total Dose = 3000ug; Inhaler No.1 = 500ug; Inhaler No.2 = 500ug; Inhaler No.3 = 500ug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental dose 5 - 6000ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 5; each patient will be instructed to take four puffs (inhalations) from each of Inhalers 1 through 3, for a total of twelve inhalations.
No. of Puffs per Inhaler = 4; Total Dose = 6000ug; Inhaler No.1 = 500ug; Inhaler No.2 = 500ug; Inhaler No.3 = 500ug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 6; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
No. of Puffs per Inhaler = 2; Total Dose = Placebo; Inhaler No.1 = Placebo; Inhaler No.2 = Placebo; Inhaler No.3 = Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ensifentrine 100mcg</intervention_name>
    <description>Single doses of RPL554 inhaled via pressurised metered dose inhaler:
Doses are - 100mcg</description>
    <arm_group_label>Experimental dose 1 - 100ug</arm_group_label>
    <other_name>RPL554</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ensifentrine 300mcg</intervention_name>
    <description>Single doses of RPL554 inhaled via pressurised metered dose inhaler:
Doses are - 300mcg</description>
    <arm_group_label>Experimental dose 2 - 300ug</arm_group_label>
    <other_name>RPL554</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ensifentrine 1000mcg</intervention_name>
    <description>single doses of RPL554 inhaled via pressurised metered dose inhaler: Doses are - 1000mcg</description>
    <arm_group_label>Experimental dose 3 - 1000ug</arm_group_label>
    <other_name>RPL554</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ensifentrine 3000mcg</intervention_name>
    <description>Single doses of RPL554 inhaled via pressurised metered dose inhaler:
Doses are - 3000mcg</description>
    <arm_group_label>Experimental dose 4 - 3000ug</arm_group_label>
    <other_name>RPL554</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ensifentrine 6000mcg</intervention_name>
    <description>Single doses of RPL554 inhaled via pressurised metered dose inhaler:
Doses are - 6000mcg</description>
    <arm_group_label>Experimental dose 5 - 6000ug</arm_group_label>
    <other_name>RPL554</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Single doses of Placebo inhaled via pressurised metered dose inhaler:
Doses are - Placebo</description>
    <arm_group_label>Placebo comparator - placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients with moderate to severe COPD, with a post bronchodilator FEV1
             of 40 to 80% of predicted and FEV1/FVC ratio of â‰¤0.70.

          -  They must have a baseline increase in FEV1 of &gt;150 mL following four puffs of
             salbutamol.

          -  They must have at least a 10 pack-year smoking history, and may be either a current or
             former smoker.

        Exclusion Criteria:

          -  Patients must be clinically stable without recent COPD exacerbations or
             hospitalisations.

          -  They must not have uncontrolled disease or chronic heart failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reynold Daniel, B.S.</last_name>
    <phone>914-860-6855</phone>
    <email>reynold.daniel@veronapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Respiratory Clinical Trials Ltd</name>
      <address>
        <city>London</city>
        <zip>W1G 8HU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Leaker</last_name>
      <phone>+44 207 034 3324</phone>
      <email>brian.leaker@heartlungcentre.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit Limited</name>
      <address>
        <city>Wythenshawe</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Singh</last_name>
      <phone>+44 161 946 4050</phone>
      <email>dsingh@meu.org.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Adults</keyword>
  <keyword>Phase II</keyword>
  <keyword>RPL554</keyword>
  <keyword>Ensifentrine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

